Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19384339 | 0.91 | GABRA1 (0.60) | KDM4EGABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL492203 | 0.89 | KDM4E (0.66) | KDM4EGABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL4782423 | 0.88 | ATM (0.54) | KDM4EGABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL4101185 | 0.84 | KDM4E (0.68) | KDM4EGSK3BPOLBMAPTELANE | |
| SCHEMBL4291226 | 0.84 | KDM4E (0.63) | KDM4EGSK3BPDPK1JAK2ELANE | |
| SCHEMBL23792137 | 0.83 | JAK2 (0.50) | KDM4EGABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL960087 | 0.83 | KDM4E (0.66) | KDM4EPOLBMAPTELANESMN1; SMN2 | |
| SCHEMBL5922444 | 0.83 | KDM4E (0.66) | KDM4EGABRA1GABRA3POLBMAPT | |
| SCHEMBL23119032 | 0.82 | GSK3B (0.48) | KDM4EGABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL23068075 | 0.82 | GSK3B (0.48) | KDM4EGABRA1GABRB1GABRA3GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071469-A | PARG inhibitor and preparation method and application thereof | 烟台新药创制山东省实验室 | 2026-05-22 | — | — | CN | disclosed |
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| EP-4522608-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2025-03-19 | — | — | EP | disclosed |
| CN-119546602-A | Pyrrolidone derivatives as inhibitors of nfkb-induced kinase | 詹森药业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2023217906-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230047396-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-20070135417-A1 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | MEMORY PHARMACEUTICALS CORPORATION | 2007-06-14 | — | — | US | disclosed |
| WO-2007056582-A1 | 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1735306-A2 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060058366-A1 | Jnk inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-10-20 | — | — | US | disclosed |
| WO-2005092890-A2 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| EP-1582211-A1 | JNK INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047396-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | WNT1, WNT3, WNT3A | KDM4E 2208/4885GABRA1 4141/4885GABRB1 2764/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | KDM4E 2795/4885GABRA1 2771/4885GABRB1 2113/4885 |
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | KDM4E 1355/4885GABRA1 3254/4885GABRB1 2155/4885 |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT3, WNT3A, WNT1 | KDM4E 3404/4885GABRA1 4801/4885GABRB1 4635/4885 |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT1, WNT3, WNT3A | KDM4E 2139/4885GABRA1 4406/4885GABRB1 3607/4885 |
| US-20070135417-A1 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | CHRNA7, CHRNA5, CHRNA3 | KDM4E 4040/4885GABRA1 64/4885GABRB1 69/4885 |
| US-20060058366-A1 | Jnk inhibitor | MAPK3, MAPK4, MAPKAPK3 | KDM4E 1238/4885GABRA1 3705/4885GABRB1 3013/4885 |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA3 | KDM4E 3317/4885GABRA1 42/4885GABRB1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.